Brenda Thompson: Daily

The CEO of Genenta Science now owns 10% of the company, all bought on the open market. What does this bold insider move signal for its cancer therapy?

A new standing wheelchair module offers unprecedented height, blending advanced engineering with profound health and social benefits for users.

A new pharma-tech alliance aims to leverage quantum computing and AI to create safer opioids, but the non-binding deal faces significant hurdles.

How ONAR Holding's newly acquired agency, JUICE, used AI to shatter holiday sales records, validating a high-stakes M&A strategy for investors.

A long-time innovator at the foundation, Cory Anderson steps into the CEO role with a vision to accelerate economic mobility for Arkansas's families.

A new study reveals a tissue allograft, AmchoPlast™, triples healing rates for diabetic foot ulcers, offering a major breakthrough for a common complication.

A Chinese startup's tiny new heart pump enters human trials, aiming to disrupt a billion-dollar market and solve a massive unmet need in cardiac care.

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

A positive EU opinion for Sobi's Aspaveli could bring the first-ever targeted treatment for two rare kidney diseases, shaking up a market desperate for innovation.

Lightbeam's new NCQA prevalidation isn't just a certificate. It's a strategic move reshaping compliance, patient outcomes, and the health tech market.

Gossamer Bio's recent 200,000-share grant to a new hire is more than a welcome bonus; it's a strategic bet on its blockbuster drug candidate.

A.D.A.M. Innovations just launched ALUNAÉ, the world's first AI genomic-based skincare. Is this the future of beauty or a step too far?

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

Vapotherm partners with Flight Medical, launching the VentO2ux ventilator to challenge market giants and redefine emergency respiratory care in the US.

A South Korean biotech's novel antibody, now named rapaprutug, could shift the paradigm for pulmonary arterial hypertension by targeting its root causes.

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

B. Braun's new ready-to-activate antibiotic system promises to save time, reduce errors, and streamline care. Here's how it could reshape hospital efficiency.

A major CRO presents 10 pivotal studies at the world's top blood disease meeting, revealing a strategy built on real-world data and collaborative innovation.

With new EHR integrations and a direct-to-provider model, Speke AI is making its ambient intelligence tools more accessible than ever. Is this the tipping point?

With a fresh $212M, Enlivex is not only advancing its osteoarthritis drug but also building a treasury on a crypto token. A revolutionary new model or a risky distraction?